JSPR
Jasper Therapeutics, Inc.Company with tickers: JSPR, JSPRW
CIK
1788028
CUSIP
471871202
Shares Outstanding
27,996,819
13F Activity (30d)
49 filings
48 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | $3,623,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Gross Profit | — | ||||
| Operating Expenses | $10,952,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Research & Development | $5,814,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Operating Income | $-10,952,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Net Income | $-1,174,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Basic) | $-0.04 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Diluted) | $-0.04 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |